Skip to content

Hysterectomy and OPPortunistic SAlpingectomy

Hysterectomy and Opportunistic Salpingectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03045965
Acronym
HOPPSA
Enrollment
4400
Registered
2017-02-08
Start date
2017-06-01
Completion date
2053-12-01
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication, Ovarian Cancer

Keywords

Salpingectomy, Hysterectomy, Ovarian cancer

Brief summary

HOPPSA is a register based randomized controlled trial (R-RCT), with the objective to examine if opportunistic salpingectomy compared with no salpingectomy, at the time of hysterectomy for a benign reason * has no increased risk of complications * has no negative side effects on ovarian function and subsequent cardiovascular disease or incidence of fractures * implies reduced risk of subsequent ovarian cancer Randomization and follow-up will be conducted within national registers.

Detailed description

High grade serous ovarian cancer, the most fatal subtype, may originate in the fimbriae of the Fallopian tubes. This theory has led to the idea of opportunistic salpingectomy as a way of decreasing the risk of epithelial ovarian cancer (EOC). HOPPSA is a national register-based RCT, with randomization and follow-up in The Swedish National Quality Register of Gynecological Surgery (Gyn/Op). HOPPSA aims to study if opportunistic salpingectomy is safe, and if it can reduce the risk of EOC. PICO P (patients). Women \<55 years, undergoing hysterectomy due to a benign reason I (intervention). Bilateral salpingectomy at the time of hysterectomy C (comparison). No salpingectomy O (outcomes). Primary short term: surgical complications reported according to Clavien-Dindo at 8 weeks post-operatively Intermediate term: change in menopausal symptoms from baseline to 1 year, assessed with Menopause Rating Scale Long term: ovarian cancer assessed through the National Cancer Register Recruitment of 4400 patients is estimated to take 4-6 years depending on the participation rate of the Swedish gynecological clinics. Data retrieval from GynOp on short and intermediate term outcomes, requiring smaller sample sizes, will be done at the end of the recruitment period. If these results, ready available when the study recruitment is closed, show that opportunistic salpingectomy does not increase surgical complications and menopausal symptoms, women can be advised to undergo salpingectomy to potentially minimize the future risk of EOC.

Interventions

PROCEDURESalpingectomy

The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.

Sponsors

Göteborg University
Lead SponsorOTHER
Vastra Gotaland Region
CollaboratorOTHER_GOV
Umeå University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Masking of the intervention is planned to include the one-year follow-up of menopausal symptoms.

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 54 Years
Healthy volunteers
No

Inclusion criteria

* Planned hysterectomy for a benign reason * Age \< 55 years at randomization * Willing to be randomized * Vaginal route may be included if the surgeon is confident with performing vaginal salpingectomy.

Exclusion criteria

* Previous bilateral oophorectomy and/or salpingectomy * Planned oophorectomy and/or salpingectomy (for reasons such as already diagnosed adnexal tumor, known carrier of the breast cancer susceptibility gene (BRCA) 1/2 mutation or Lynch syndrome (hereditary nonpolyposis colorectal cancer)) * Non-understanding of the oral or written study information

Design outcomes

Primary

MeasureTime frameDescription
Surgical complication - short term primary outcomeEight weeks post-operativeDichotomous outcome, retrieved from any of two sources in the GynOp register: specified question on complications and the Clavien-Dindo classification
Change in menopausal symptom score - intermediate term primary outcomeOne year after surgeryMeasured from baseline to one year follow-up, assessed with Menopause Rating Scale (MRS)
Epithelial ovarian cancer - long term primary outcome10-30 years after surgeryThe outcome is dichotomous, the diagnosis is classified according to ICD10. Each case with a positive outcome is further described with histopathological types and grade, as well as clinical stage according to International Federation of Gynecology and Obstetrics (FIGO). Assessed through national registers stage according to International Federation of Gynecology and Obstetrics (FIGO). Assessed through national registers

Secondary

MeasureTime frameDescription
Operative timeAt day of surgeryContinous outcome, registered in minutes
Length of hospital stayAssessment will be done at discharge from hospital after surgery, including a period up to 8 weeks. aContinous outcome, registered in days
Perioperative blood lossAt day of surgeryContinous outcome, registered in ml
Conversion to other surgical routeAt day of surgeryDichotomous outcome
Failure rate of salpingectomy at planned vaginal hysterectomyAt day of surgeryDichotomous outcome
Prevalence of menopausal symptoms of at least moderate level according to Menopause Rating Scale (MRS)One and five years after surgeryDichotomous outcome based on MRS
Ovarian function, measured as change in anti-Müllerian hormone (AMH) serum level, from baselineOne year after surgeryContinous outcome, measured in mg/L
Subsequent adnexal surgery, including all surgery engaging salpinges and/or ovariesAt one and up to ten years after surgeryDichotomous outcome, accompanied by a description of number and types of surgery performed
Use of Hormone Replacement Therapy (HRT)At one and up to ten years after surgeryDichotomous outcome
Cardiovascular disease10-30 years after surgeryDichotomous outcome, accompanied by the specific ICD diagnoses
Fractures (primarily radial, vertebral and hip fractures)10-30 years after surgeryDichotomous outcome, accompanied by the specific ICD diagnoses

Countries

Sweden

Contacts

PRINCIPAL_INVESTIGATORAnnika Strandell

Sahlgrenska University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026